September 11, 2017 / 11:42 AM / 10 months ago

BRIEF-Essa Pharma announces results from the phase 1 clinical trial of EPI-506

Sept 11 (Reuters) - Essa Pharma Inc

* Essa Pharma announces results from the phase 1 clinical trial of epi-506 for treatment of MCRPC and updates clinical and strategic plans

* Confirmed EPI-506 is well-tolerated with a favorable safety profile​

* Essa initiates corporate restructuring to refocus research and development efforts​

* Makes strategic decision to prioritize Aniten program for MCRPC over further clinical development of epi-506​

* Corporate restructuring associated with updated clinical plan expected to lower capex in fiscal 2018 by about $7 million versus fiscal 2017

* Anticipates that its current resources are sufficient to support planned operations into fourth calendar quarter of 2017​

* Essa will discontinue further clinical development of EPI-506

* Will implement a corporate restructuring plan to focus research and development resources on its next-generation Anitens targeting AR-NTD​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below